102 related articles for article (PubMed ID: 23428312)
1. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Weiss J; Haefeli WE
Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Rickert V; Haefeli WE; Weiss J
Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
Weiss J; Becker JP; Haefeli WE
Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
[TBL] [Abstract][Full Text] [Related]
4. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
5. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
Zembruski NC; Büchel G; Jödicke L; Herzog M; Haefeli WE; Weiss J
J Antimicrob Chemother; 2011 Apr; 66(4):802-12. PubMed ID: 21393174
[TBL] [Abstract][Full Text] [Related]
6. Impact of drug transporters on cellular resistance towards saquinavir and darunavir.
König SK; Herzog M; Theile D; Zembruski N; Haefeli WE; Weiss J
J Antimicrob Chemother; 2010 Nov; 65(11):2319-28. PubMed ID: 20817741
[TBL] [Abstract][Full Text] [Related]
7. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.
Weiss J; Theile D; Rüppell MA; Speck T; Spalwisz A; Haefeli WE
Eur J Pharmacol; 2013 Feb; 701(1-3):168-75. PubMed ID: 23353592
[TBL] [Abstract][Full Text] [Related]
8. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
Weiss J; Theile D; Dvorak Z; Haefeli WE
Pharmaceutics; 2014 Dec; 6(4):632-50. PubMed ID: 25521244
[TBL] [Abstract][Full Text] [Related]
9. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
Blank A; Meier K; Urban S; Haefeli WE; Weiss J
Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
[TBL] [Abstract][Full Text] [Related]
10. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
11. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
Weiss J; Baumann S; Theile D; Haefeli WE
Pulm Pharmacol Ther; 2015 Feb; 30():80-6. PubMed ID: 25535031
[TBL] [Abstract][Full Text] [Related]
12. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Weiss J; Kocher J; Mueller C; Rosenzweig S; Theile D
Biopharm Drug Dispos; 2017 Dec; 38(9):517-525. PubMed ID: 28865089
[TBL] [Abstract][Full Text] [Related]
13. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.
Bexten M; Oswald S; Grube M; Jia J; Graf T; Zimmermann U; Rodewald K; Zolk O; Schwantes U; Siegmund W; Keiser M
Mol Pharm; 2015 Jan; 12(1):171-8. PubMed ID: 25466967
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression.
Genovese S; Epifano F; Curini M; Menger D; Zembruski NC; Weiss J
Phytomedicine; 2011 May; 18(7):586-91. PubMed ID: 21112752
[TBL] [Abstract][Full Text] [Related]
15. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
16. Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors.
Sharma D; Lau AJ; Sherman MA; Chang TK
Biochem Pharmacol; 2013 Jun; 85(11):1700-11. PubMed ID: 23583259
[TBL] [Abstract][Full Text] [Related]
17. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
Yamazaki M; Li B; Louie SW; Pudvah NT; Stocco R; Wong W; Abramovitz M; Demartis A; Laufer R; Hochman JH; Prueksaritanont T; Lin JH
Xenobiotica; 2005 Jul; 35(7):737-53. PubMed ID: 16316932
[TBL] [Abstract][Full Text] [Related]
18. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters.
Weiss J; Bajraktari-Sylejmani G; Haefeli WE
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32992777
[TBL] [Abstract][Full Text] [Related]
19. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.
Weiss J; Gajek T; Köhler BC; Haefeli WE
Pharmaceutics; 2016 Feb; 8(1):. PubMed ID: 26927160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
